Figure 3.
Molecular structures of lipids used in gene therapy formulations and discussed throughout the text. (a) Typical zwitterionic (1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)) and neutral lipids (monoolein (MO) and Cholesterol). (b) Typical cationic lipids (1,2-dioleoyl-3-trimethylammonium propane (DOTAP), dimethyldioctadecylammonium bromide (DODAB), didodecyldimethylammonium bromide (DDAB) and cetyltrimethylammonium bromide (CTAB)). (c) PEGylated lipid with DOPE backbone and PEG Mw of ca. 2000 Da. (d) Ionizable cationic lipids (1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2DMA), O-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino)butanoate (DLinMC3DMA) and 2-(dimethylamino)propyl-(12Z,15Z)-3-((9Z,12Z)-octadeca-9,12-dien-1-yl)henicosa-2,12,15-trienoate (YSK13-C3). (e) Multivalent cationic lipid N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide (MVL5, nominal charge of +5) and dendritic headgroup cationic lipid N1-2-[((1S)-1,4-di[(1S)-1,4-di((1S)-1,4-di[(3-aminopropyl)amino]-butylcarboxamido)butyl]carboxamidobutyl)carboxamido]ethyl-3,4-di[(Z)-9-octadecenyloxy]benzamide (MVLBG2, nominal charge of +16).
